TVGN TEVOGEN BIO HOLDINGS INC

Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference

Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference

WARREN, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today the company will host an AI panel during the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The panel, titled "AI in Biopharma: Next Frontier of Medical Innovation," will explore the transformative potential of artificial intelligence in the biopharma industry. Panelists will include Dr. David Rhew, Global Chief Medical Officer & VP of Healthcare of Microsoft (Nasdaq: ), Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, and Dr. Sean Tunis, Principal of Rubix Health.

The discussion will highlight how AI-driven technologies can revolutionize drug discovery, accelerate development timelines, enhance patient accessibility, foster quicker innovation, and significantly reduce operating costs. Attendees can expect insights into how Tevogen.AI is leveraging advanced AI capabilities to advance precision T cell therapies for infectious diseases, cancers, and neurological disorders.

Event Details

Date:

Monday, January 13, 2025

Location:

Marines' Memorial Club & Hotel, 609 Sutter St, San Francisco, CA 94102

Time (PST):

2:00 PM – 2:30 PM – AI in Biopharma: Next Frontier of Medical Innovation

2:30 PM – 3:15 PM – Afternoon Coffee Break

3:15 PM – 4:00 PM – Pioneering the Economics of Health: Balancing Access and Outcomes

4:00 PM – 6:00 PM – Reception and Cocktails

For inquiries regarding additional event details, please contact .

About Tevogen Bio

Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.

Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701



EN
23/12/2024

Underlying

TVGNTEVOGEN BIO HOLDINGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TEVOGEN BIO HOLDINGS INC

 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Letter to Shareholders from CEO Dr. Ryan Saadi

Letter to Shareholders from CEO Dr. Ryan Saadi WARREN, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ). Dear Shareholders, As we continue executing on Tevogen’s long-term strategy to evolve into a sustainable, revenue-generating healthcare enterprise, I would like to provide an update regarding our ongoing strategic initiatives. Over the past several months, we have been actively evaluating potential acquisitions designed to complement our existing immunotherapy and artificial intelligence platforms. If consummated, these transactions are...

2h / 4m 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate...

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical WARREN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with Apozeal Pharmaceutical Inc. (“Apozeal”), a pharmaceutical company focused on the development and manufacturing of high-quality, cost-effective medicines. The proposed transaction represents a strategic step in advancing Tevogen...

March 5, 2026 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Announces Reverse Stock Split

Tevogen Announces Reverse Stock Split WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of its common stock at a ratio of 50 for 1. Stockholders previously approved the reverse stock split on February 19, 2026, and provided the Board with discretion to determine the final reverse stock split ratio. The reverse stock split is being conducted to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Gl...

March 4, 2026 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a ...

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organization (“CRO”). If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the Company’s evolution into a revenue-generating healthcare enterp...

February 27, 2026 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisit...

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) --   (“Tevogen Bio Holdings Inc.”) (Nasdaq: ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with (“Sciometrix”), a privately held healthcare technology and value-based care solutions provider headquartered in Michigan and developer of the Clinicus digital care management platform, that would, if ...

February 26, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch